Oncology
ONCOLOGY Vol 19 No 14
Volume: 19
Issue: 14
ONCOLOGY Vol 19 No 12
Volume: 19
Issue: 12
ONCOLOGY Vol 19 No 13_Suppl_6
Volume: 19
Issue: 13_Suppl_6
ONCOLOGY Vol 19 No 13_Suppl_5
Volume: 19
Issue: 13_Suppl_5
ONCOLOGY Vol 19 No 11_Suppl_4
Volume: 19
Issue: 11_Suppl_4
ONCOLOGY Vol 19 No 10
Volume: 19
Issue: 10
ONCOLOGY Vol 19 No 13
Volume: 19
Issue: 13
ONCOLOGY Vol 19 No 8
Volume: 19
Issue: 8
ONCOLOGY Vol 19 No 11
Volume: 19
Issue: 11
ONCOLOGY Vol 19 No 9
Volume: 19
Issue: 9
ONCOLOGY Vol 19 No 7
Volume: 19
Issue: 7
ONCOLOGY Vol 19 No 5
Volume: 19
Issue: 5
ONCOLOGY Vol 19 No 6
Volume: 19
Issue: 6
ONCOLOGY Vol 19 No 4_Suppl_3
Volume: 19
Issue: 4_Suppl_3
ONCOLOGY Vol 19 No 4_Suppl_2
Volume: 19
Issue: 4_Suppl_2
ONCOLOGY Vol 19 No 4_Suppl_1
Volume: 19
Issue: 4_Suppl_1
ONCOLOGY Vol 19 No 4
Volume: 19
Issue: 4
ONCOLOGY Vol 19 No 3
Volume: 19
Issue: 3
ONCOLOGY Vol 19 No 2
Volume: 19
Issue: 2
ONCOLOGY Vol 19 No 1
Volume: 19
Issue: 1
Advertisement
Advertisement
Trending on CancerNetwork
1
Pembrolizumab Combo Significantly Improves PFS/OS in Recurrent PROC
2
Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC
3
Tarlatamab Improves Survival Vs Chemotherapy in Second-Line SCLC Subgroups
4
Tarlatamab Plus Chemo/IO Regimens Are Safe, Elicit Responses in ES-SCLC
5
